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BACKGROUND: Angiotensin-converting enzyme inhibitors (ACE) and
angiotensin receptor blockers (ARB) improve cardiovascular outcomes
in high-risk individuals with diabetes. Despite the marked benefit, it is
unknown what percentage of patients with diabetes would benefit from
and what percentage actually receive this preventive therapy.
OBJECTIVES: To examine the proportion of older diabetic patients
with indications for ACE or ARB (ACE/ARB). To generate national es-
timates of ACE/ARB use.
DESIGN AND PARTICIPANTS: Survey of 742 individuals55 years
(representing 8.02 million U.S. adults) self-reporting diabetes in the
1999 to 2002 National Health and Nutrition Examination Survey.
MEASUREMENTS: Prevalence of guideline indications (albuminuria,
cardiovascular disease, hypertension) and other cardiac risk factors
(hyperlipidemia, smoking) with potential benefit from ACE/ARB. Prev-
alence of ACE/ARB use overall and by clinical indication.
RESULTS: Ninety-two percent had guideline indications for ACE/ARB.
Including additional cardiac risk factors, the entire (100%) U.S. non-
institutionalized older population with diabetes had indications for
ACE/ARB. Overall, 43% of the population received ACE/ARB. Hyper-
tension was associated with higher rates of ACE/ARB use, while albu-
minuria and cardiovascular disease were not. As the number of
indications increased, rates of use increased, however, the maximum
prevalence of use was only 53% in individuals with 4 or more indica-
tions for ACE/ARB.
CONCLUSIONS: ACE/ARB is indicated in virtually all older individuals
with diabetes; yet, national rates of use are disturbingly low and key
risk factors (albuminuria and cardiovascular disease) are being missed.
To improve quality of diabetes care nationally, use of ACE/ARB therapy
by ALL older diabetics may be a desirable addition to diabetes per-
formance measurement sets.
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T he worsening ‘‘epidemic’’ of diabetes in the UnitedStates1,2 makes the use of effective secondary prevention
critical to reducing excess morbidity, mortality, and costs. The
elderly bear a disproportionate burden of diabetes with up to
18% of older individuals having diagnosed disease.1,3,4 Angio-
tensin-converting enzyme inhibitors (ACE) and angiotensin re-
ceptor blockers (ARB) have been shown to prevent both cardiac
and renal end-organ damage in diabetes.5–21 Despite the
marked morbidity and mortality benefits of these agents, no
nationally representative studies have examined what percent-
age of older patients with diabetes would benefit from and
what percentage actually receive this important preventive
therapy. Therefore, the objectives of this study were to exam-
ine the proportion of older diabetic patients with clinical indi-
cations for ACE or ARB (ACE/ARB) therapy, and to generate
national estimates of ACE/ARB use.
METHODS
Study Sample
The National Health and Nutrition Examination Survey
(NHANES), a nationally representative cross-sectional survey
of the U.S. noninstitutionalized civilian population, uses a
complex, multistage, probability sample design, with oversam-
pling of the elderly to allow for improved prevalence estimation
of health indicators in this group. Beginning in 1999, NHANES
became a continuous survey with data released in 2-year in-
crements. The current study is based on the first 4 years (1999
to 2002) of the continuous NHANES.
We selected all respondents aged 55 years or older who
responded ‘‘yes’’ to the question, ‘‘other than during pregnan-
cy, have you ever been told by a doctor or health professional
that you have diabetes or sugar diabetes?’’ Age 55 was used as
a cutoff because recent trials of the cardiovascular benefits of
ACE inhibitors limited inclusion to individuals with diabe-
tes55 years.13,14
Indications for ACE/ARB Therapy
Several national guidelines recommend ACE inhibitors or
ARBs for individuals with diabetes and select additional risk
factors, including albuminuria, cardiovascular disease, con-
gestive heart failure, and hypertension.22–25 We grouped indi-
viduals with any one (or more) of these risk factors as having
‘‘guideline indications’’ for ACE/ARB. In addition to guideline
indications, we explored two additional cardiac risk factors,
hyperlipidemia and smoking, both of which have been used as
inclusion criteria in trials demonstrating cardiovascular
benefit from ACE or ARB13,14 in individuals with diabetes.
Analyses were performed with and without the inclusion of
these two additional risk factors as indications for ACE/ARB.
Albuminuria. Albuminuria (including microalbuminuria or
macroalbuminuria) was considered present if a respondent’s
urinary albumin to creatinine ratio was30 mg/g or urine al-
bumin concentration was30 mg/L on a random, untimed
urine specimen obtained at the NHANES Mobile Examination
Center.
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Cardiovascular Disease. Cardiovascular disease was con-
sidered present if a respondent self-reported a prior physician
diagnosis of congestive heart failure, coronary artery disease,
angina pectoris, myocardial infarction, or stroke.
Hypertension. Individuals were classified as hypertensive if
they reported a prior physician diagnosis of hypertension, or
had a mean systolic blood pressure130mmHg or a mean
diastolic blood pressure85 mmHg on examination. Over
90% of respondents had 3 or more measurements for averag-
ing, and the 130/85 threshold was based on JNC VI recom-
mendations for individuals with diabetes.26
Other Indications. Smoking status was based on self-reported
current or past smoking history. Hyperlipidemia was consider-
ed present if a respondent self-reported a prior physician
diagnosis of high cholesterol or they had an LDL cholesterol
4130mg/dL on fasting laboratory measurement.
Prescription Medications in NHANES
National Health and Nutrition Examination Survey respond-
ents were asked during their in-home interview to present the
containers of all prescription medications taken in the past
month and to report any additional medications used for
which containers were not available. All medication names
were entered (during the home interview) by a trained inter-
viewer into a handheld computer and matched to an annually
updated comprehensive database of all prescription (and some
nonprescription) drugs available in the U.S. market. Over 92%
of medications had an exact match during the home interview.
The remaining 8% of medications were manually reviewed
later at the National Center for Health Statistics (NCHS).
NCHS quality control activities, such as translation of medi-
cation names into English, correction of transcription errors,
and removal of nonprescription dietary supplements from the
prescription medication files resulted in less than 1% of med-
ications listed as unknown.27,28
Respondents could have up to 20 medications recorded
although none had all 20 medication fields filled. While
NHANES uses the Federal Drug Administration’s (FDA) Na-
tional Drug Code (NDC) database to map medications to ther-
apeutic classes, the FDA withdrew its support of this system
(pending review and update) in the beginning of 2005. There-
fore, for the current study, the first author (a trained physician
researcher) reviewed the names of all medications used by this
study’s sample to identify ACE inhibitors and ARBs. A second
review was performed by the same author 1 week later, and
ACE/ARB use was successfully categorized in 99% of cases.
The one discrepant record was reviewed and corrected by an-
other physician.
Use of ACE/ARB Therapy
An individual was classified as on therapy if any of their med-
ications included an ACE or ARB. Contraindications to treat-
ment were considered rare because most individuals not
tolerating an ACE can receive an ARB with a low likelihood of
side effects.29,30
Statistical Analyses
We estimated the prevalence of risk factors that were indica-
tions for ACE/ARB. Within the overall population and in sub-
groups with differing clinical indications, we estimated
national rates of ACE/ARB use. Comparisons were assessed
using unpaired t-tests for continuous variables and Wald w2
tests for categorical variables. Logistic regression was used to
determine the predictors of ACE/ARB use. Potential predictive
variables included age, gender, race (non-Hispanic white, non-
Hispanic black, Hispanic, other), and the presence or absence
of each of the clinical indications for ACE/ARB. Bivariate odds
ratios (ORs) for being on an ACE/ARB were calculated for
each predictive variable. Multivariable logistic regression was
performed using stepwise selection with the 3 guideline indi-
cations for ACE/ARB (hypertension, albuminuria, cardiovas-
cular disease) kept in the model regardless of statistical
significance to reflect their clinical significance as indicators
to initiate ACE/ARB.
United States population estimates were obtained using
NHANES sampling weights that account for the unequal prob-
abilities of selection, nonresponse, and oversampling; stand-
ard errors were estimated using Taylor series linearization as
recommended for the NHANES 1999 to 2002 survey data.31
Analyses were performed using SAS-callable SUDAAN, version
8.0 (Research Triangle Institute, NC).
RESULTS
The study sample included 742 respondents, representing a
population of 8.02 million U.S. adults 55 years or older with
diabetes. Fifty-seven percent were between 55 and 69 years,
38% between 70 and 84 years, and 5% over 85 years. Half
(54%) were female, and 28% comprised ethnic minority
groups: 13% Hispanic, 15% non-Hispanic black.
Ninety-two percent had at least one guideline indication
for ACE/ARB use. Including other cardiac risk factors as in-
dications, 100% had an indication for ACE/ARB. Fourteen
percent of the population had one indication, 37% 2 indica-
tions, 33% 3 indications, and 16% had 4 or more indications
for ACE/ARB. The prevalence of each risk factor is given in
Table 1.
Overall, 43% of the population was on an ACE or ARB. As
the number of indications for ACE/ARB increased from 0 to 5,
ACE/ARB use increased from 0% to 53%, respectively (P=.009
for trend). Rates of ACE/ARB use associated with each indica-
tion are reported in Table 1. On bivariate analyses, none of the
demographic characteristics were associated with ACE/ARB
use, and the only clinical indication significantly associated
with increased ACE/ARB use was the presence of hypertension
(Table 1). On multivariable modeling, hypertension remained
the only significant predictor of increased ACE/ARB use (ad-
justed OR 3.36, 95% confidence interval [CI] 1.59, 7.12). Pre-
existing cardiovascular disease tended to be associated with
higher rates of ACE/ARB use (adjusted OR 1.55; 95% CI 0.98,
2.46), while albuminuria was not associated with ACE/ARB use
(adjusted OR 1.22; 95% CI 0.79, 1.89).
DISCUSSION
In a national sample of older individuals with diabetes, be-
tween 92% and 100% of patients had important clinical indi-
cations for ACE/ARB. Among these patients, ACE/ARB use
was low, with an overall rate of 43%. While ACE/ARB use in-
creased with increasing number of clinical indications, the
highest rates of use (53% in individuals with diabetes and 4
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or more additional indications for treatment) remained dis-
turbingly low. Further, in patients with risk factors indicating
clear mortality benefit from ACE/ARB, while hypertension was
associated with higher rates of ACE/ARB use, albuminuria
and preexisting cardiovascular disease were not, suggesting a
major quality problem.
To our knowledge, this is the first nationally representa-
tive study to ask what proportion of older patients with diabe-
tes would benefit from renin-angiotensin system blockade. As
in past studies, we found that cardiovascular disease risk fac-
tors (including renal dysfunction) are highly prevalent in indi-
viduals with diabetes.32 Expanding on prior studies, we
document that nationally, the vast majority (92% to 100%) of
older individuals with diabetes have clinical indications for
ACE/ARB therapy.
This is also the first study to examine national rates of
ACE/ARB use with data collected after guidelines started rec-
ommending ACE or ARB22–24 for high-risk clinical subgroups
with diabetes. In NHANES III, 13% of diabetics40 years were
on an ACE/ARB33; however, these data were collected between
1988 and 1994, a time before much of the evidence for ACE/
ARB in diabetes existed. Smaller single-institution or state-
based studies found rates of use ranging from 40% to 45% de-
pending on the setting and clinical risk of the population.34–37
One recent study in a large managed care plan found rates of
ACE/ARB use between 54% and 74% in diabetic patients with
hypertension or albuminuria, suggesting that it is possible to
increase rates of use.38 In contrast to the current community-
based study, that study lacked information on preexisting car-
diovascular disease (a key indication for ACE/ARB) and was
limited to an employed, fully insured population enrolled in a
health plan that had quality improvement tools in place spe-
cifically designed to increase ACE/ARB use in enrollees with
diabetes. In the current study, despite nearly universal indi-
cation for treatment, only 43% of older diabetics received ACE/
ARB and, in the highest risk groups (those with 4 or more in-
dications), the likelihood of being on an ACE/ARB (53%) was
not much higher than the toss of a coin.
A critical finding of the current study is the absence of
significantly higher rates of ACE/ARB use in the setting of al-
buminuria or preexisting cardiovascular disease, both of
which markedly increase cardiovascular risk in individuals
with diabetes.21,39–42 Despite clear guideline indications for
ACE/ARB in diabetic patients with albuminuria or cardiovas-
cular disease,22–25 our results suggest that the presence of
these risk factors may not be prompting physicians to initiate
ACE/ARB therapy, indicating an important quality gap.
These findings may have important implications for im-
proving the quality of diabetes care in the United States. Indi-
cations for therapy are highly prevalent (nearly universal),
rates of receipt of therapy are disturbingly low, and key indi-
cations for ACE/ARB are being missed. Our current approach
to determining candidacy for ACE/ARB therapy is to measure
risk factors and treat accordingly. However, we have subopti-
mal rates of screening for some risk factors (only 41% of dia-
betic patients enrolled in HEDIS-reporting health plans in
2000 were screened for microalbuminuria43) and, in turn,
suboptimal rates of appropriate treatment when risk factors
are identified. If we are underdiagnosing risk factors and then
undertreating those with diagnosed risk factors, the effectively
treated population is just a fraction of the population that
would benefit from treatment. Given that indications for ACE/
ARB therapy are so prevalent in this population, it may be time
to simplify our treatment algorithms by expanding indications
for ACE/ARB to include all older individuals with diabetes re-
gardless of their measured risk factors.
This study had some limitations. The NHANES 1999 to
2002 survey had a small sample size, which likely contributed
to the lack of cardiovascular disease as a statistically signifi-
cant predictor of ACE/ARB use. However, even if sample sizes
increased (CIs tightened) such that we found a ‘‘statistically
significant’’ difference in ACE/ARB use among those with and
without cardiovascular disease, the quality problem remains
unchanged: only half of diabetic patients with cardiovascular
disease are on this life-saving therapy. In large part, our meas-
ures of risk factors and ACE/ARB use were based on self-re-
port. Because we were unable to ascertain histories of adverse
reactions to ACE, we could not exclude all individuals with
contraindications to treatment. However, we would expect any
bias to be small because our end point was a composite of ACE
or ARB use and absolute contraindications to ARBs in those
not tolerating ACE are rare (angioedema or refractory hype-
rkalemia occurs in o2%).44,45 Finally, the current study ex-
plored the prevalence of indications for and treatment with
Table 1. Indications for and Treatment with ACE/ARB
Risk Factors Prevalence (%) Rates of ACE/ARB Use for Each Indication
With Indication (%) Without Indication (%) OR (95% CI)
Guideline-based
Cardiovascular disease 34.5 50.5 39.8 1.54 (0.95, 2.50)
Albuminuria 41.1 46.8 43.2 1.08 (0.68, 1.71)
Hypertension 82.8 48.1 21.0 3.41 (1.81, 6.41)
Other cardiovascular
Hyperlipidemia 72.9 43.6 43.2 1.01 (0.60, 1.71)
Current smoker 24.0 43.2 43.5 0.84 (0.45, 1.56)
Number of indicationsw
One 15.9 35.7 – –
Two 39.2 38.9
Three 30.4 51.6
Four or more 12.8 53.4
Risk factors are not mutually exclusive.
wP=.009 for trend.
ACE,angiotensin-converting enzyme; ARB, angiotensin receptor blockers; OR, odds ratio; CI, confidence interval.
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ACE/ARB during a time period (1999 to 2002) in which the
evidence base for their use in diabetes was still being devel-
oped. While the current evidence base is substantially strong-
er, guidelines for ACE use in diabetic patients with
hypertension (1997), albuminuria (1995), and congestive
heart failure (1994) were in place well before this survey was
initiated.22–24
CONCLUSION
Renin-angiotensin system blockade in individuals with diabe-
tes is associated with decreases in cardiovascular events and
renal failure. This analysis demonstrates that in 1999 to 2002,
the entire (100%) noninstitutionalized U.S. population over the
age of 55 with diagnosed diabetes would have benefited from
ACE/ARB; yet, only 43% received it. Despite guideline indica-
tions, it appears that neither albuminuria nor cardiovascular
disease are prompting increased rates of ACE/ARB use. To
further increase ACE/ARB use and improve cardiovascular
outcomes, it may be desirable to create a measure of ACE/ARB
use for ALL older individuals with diabetes for inclusion in fu-
ture diabetes performance measurement sets.
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